Niagen Bioscience (NAGE) Common Equity (2011 - 2026)

Niagen Bioscience (NAGE) has 15 years of Common Equity data on file, last reported at $82.3 million in Q1 2026.

• On a quarterly basis, Common Equity rose 48.76% year-over-year to $82.3 million in Q1 2026; TTM through Mar 2026 was $82.3 million, a 48.76% increase from a year earlier, with the FY2025 full-year figure at $76.5 million, up 66.04% from the prior year.
• Common Equity for Q1 2026 stood at $82.3 million, up from $76.5 million in the prior quarter.
• Over the last five years, Common Equity for NAGE reached as high as $82.3 million in Q1 2026 and fell as low as $20.8 million in Q2 2022.
• Historically, Common Equity has averaged $41.0 million across 5 years, with a median of $29.0 million in 2024.
• Across the five-year window, Common Equity plunged 50.7% in 2022 and surged 108.98% in 2025, its largest moves.
• Year by year, Common Equity stood at $28.7 million in 2022, then retreated by 0.75% to $28.5 million in 2023, then jumped by 61.98% to $46.1 million in 2024, then jumped by 66.04% to $76.5 million in 2025, then increased by 7.57% to $82.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $82.3 million in Q1 2026, $76.5 million in Q4 2025, and $70.7 million in Q3 2025.